rac-1,2-di-O-(octadec-9-en-1-yl)glycerol | 81410-63-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: rac-1,2-di-O-(octadec-9-en-1-yl)glycerol
• 英文别名: 2,3-Bis(octadec-9-enoxy)propan-1-ol
• CAS: 81410-63-1
• 化学式: C₃₉H₇₆O₃
• 分子量: 593.031
• InChiKey: HCTYOHVVRRHDTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.1
• 重原子数：
  42
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  rac-1,2-di-O-(octadec-9-en-1-yl)glycerol 在 三乙胺 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 68.0h， 生成 rac-N-[2,3-di(octadec-9-en-1-yloxy)prop-1-yl]-N'-methylimidazolium methanesulfonate
  参考文献：
  名称：

  Synthesis of alkyl glycerolipids with various cationic groups linked directly to the glycerol backbone

  摘要：

  A number of positively charged lipids containing pyridinium, N-methylmorpholinium, N-methylimidazolinium, 4-N,N-dimethylaminopyridinium, and 4-N,N-dimethylcyclohexylammonium groups linked directly to the C(3) atom of 1,2-di-O-alkylglycerols with Br-, MsO-, and TsO- anions as counterions were synthesized.

  DOI：

  10.1007/bf02495307

文献信息

• COMPOUNDS USEFUL FOR INHIBITING CDK7
  申请人：Eli Lilly and Company

  公开号：US20190144456A1

  公开（公告）日：2019-05-16

  The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.

  本发明提供了新型的CDK7抑制剂及其药物组合物：或其药物可接受的盐。
• Inhibitors of phospholipase enzymes
  申请人：American Home Products Corporation

  公开号：US20030153751A1

  公开（公告）日：2003-08-14

  Novel compounds are disclosed which inhibit the activity of phospholipase enzymes in a mammal, particularly cytosolic phospholipase A 2 . Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.

  本发明披露了一种新型化合物，可抑制哺乳动物中磷脂酶酶活性，特别是细胞质磷脂酶A2。本发明还披露了包括这些化合物的制药组合物和使用这些组合物的治疗方法。
• Di-Vanilloyl And Tri-Vanilloyl Derivatives For Use In Anti-Cancer Therapy
  申请人：Kiss Robert

  公开号：US20110280940A1

  公开（公告）日：2011-11-17

  The invention relates to the medical field, more precisely in the field of anti-cancer treatment and treatment of Alzheimer's disease, Parkinson's disease or Pick's disease or for ameliorating symptoms of Down syndrome, providing newly synthesised multi-vanilloyl derivative compounds and their use in the treatment of said disorders.

  该发明涉及医学领域，更精确地说是抗癌治疗和治疗阿尔茨海默病、帕金森病或皮克氏病或改善唐氏综合症症状的领域，提供新合成的多香豆酰衍生物化合物及其在治疗上述疾病中的应用。
• DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0685234A1

  公开（公告）日：1995-12-06

  The invention aims at effectively utilizing a single-stranded nucleic acid copolymer, in particular, poly(adenylic acid-uridylic acid) and providing a drug composition having an antitumor effect. An example of the drug composition of the invention is one containing a lipid device, such as Lipofecting®, 3-O-(4-dimethylaminobutanoyl)-1,2-O-dioleylglycerol, 3-O-(2-dimethylaminoethyl)carbamoyl-1,2-O-dioleylglycerol, 3-O-(2-diethylaminoethyl)-carbamoyl-1,2-O-dioleylglycerol or 2-O-(2-diethyl-aminoethyl)carbamoyl-1,3-O-dioleylglycerol, and poly(adenylic acid-uridylic acid).

  本发明旨在有效利用单链核酸共聚物，特别是聚（腺嘌呤核酸-尿苷酸），并提供一种具有抗肿瘤效果的药物组合物。本发明药物组合物的一个例子是含有脂质装置，如 Lipofecting®、3-O-(4-二甲基氨基丁酰基)-1,2-O-二油酸甘油、3-O-(2-二甲基氨基乙基)氨基甲酰基-1、2-O-二烯丙基甘油、3-O-(2-二乙基氨基乙基)氨基甲酰基-1,2-O-二烯丙基甘油或 2-O-(2-二乙基氨基乙基)氨基甲酰基-1,3-O-二烯丙基甘油，以及聚(腺嘌呤核苷酸)。
• GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION
  申请人：NIPPON SHINYAKU COMPANY, LIMITED

  公开号：EP0685457A1

  公开（公告）日：1995-12-06

  The invention aims at providing a device comprising lipids that act like the so-called cationic liposome and are reduced in toxicity and the lipids as the constituent of the device. The invention compounds are exemplified by 3-0-(4-dimethylaminobutanoyl)-1,2-0-dioleylglycerol, 3-0-(2-dimethylaminoethyl)carbamoyl-1,2-0-dioleylglycerol, 3-0-(2-diethylaminoethyl)carbamoyl-1,2-0-dioleylglycerol, and 2-0-(2-diethylaminoethyl)-carbamoyl-1,3-0-dioleylglycerol. The device comprises these lipids and phospholipids. The device enables, when administered together with, for example, a double-stranded RNA, the RNA to migrate to the action site safely.

  本发明旨在提供一种由脂质组成的装置，这种脂质的作用类似于所谓的阳离子脂质体，并且毒性较低，脂质是该装置的组成成分。本发明化合物的例子有 3-0-（4-二甲基氨基丁酰基）-1,2-0-二油基甘油、3-0-（2-二甲基氨基乙基）氨基甲酰基-1,2-0-二油基甘油、3-0-（2-二乙基氨基乙基）氨基甲酰基-1,2-0-二油基甘油和 2-0-（2-二乙基氨基乙基）氨基甲酰基-1,3-0-二油基甘油。该装置由这些脂类和磷脂组成。该装置在与双链 RNA 等一起给药时，可使 RNA 安全地迁移到作用位点。